Abstract:Background: Regulatory T (Treg) cells in the tumor microenvironment have an immune suppressive function, and their presence is associated with poor prognosis. Depletion of Treg cells may be a mechanism to sensitize tumors and represents a novel strategy for cancer immunotherapy. High expression of chemokine receptor CCR8 has been found in Treg cells in microenvironments of numerous tumors but not on Treg cells in systemic lymphoid tissues. The ability to selectively kill Treg cells in tumor environments may provide an opportunity for therapy that leaves Treg function intact elsewhere in the body where they normally mediate tolerance to self-antigen. Methods: We sought to identify CCR8 antibodies for therapeutics and designed an antibody discovery strategy to address the challenges of this target. CCR8 is a member of the G protein-coupled receptor (GPCR) family. Like many GPCRs, CCR8 is a valuable therapeutic antibody target but challenging to access due to its poor expression, membrane-dependent structure, and poor immunogenicity due to sequence conservation. We developed an antibody discovery platform (MPS) that specifically addresses each of these challenges through use of advanced immunization techniques and evolutionarily divergent host species (chickens) for robust immune responses against conserved targets. We extensively engineered CCR8 antigen to enable high expression for immunization. When sufficient antibody diversity was not obtained using our standard immunization techniques, we developed mRNA immunization techniques for this program. Antibody binding was measured using flow cytometry on transfected cells and human Treg cells. The ability of antibodies to inhibit CCR8 function was measured using intracellular calcium influx assays. Antibody internalization was measured using dye uptake assays and flow cytometry. Antibodies were conjugated with cytotoxic payloads and tested for the ability to mediate killing. Results: Using these approaches, we identified a panel of high-affinity antibodies that bound in the nanomolar or subnanomolar range with high specificity, and we selected a lead molecule to progress. We will present data from our antibody discovery campaign including mRNA immunization, binding profiles, GPCR functional data, receptor-mediated internalization, and the ability of antibody-drug conjugates (ADC) to kill CCR8+ cells, including human Treg cells, in vitro. Conclusion: Treg cells are a primary driver of the immunosuppressive microenvironment in many solid tumors. Targeting immune-suppressive CCR8+ Treg cells using ADC has potential to expand the treatment of solid tumors Citation Format: Lewis J. Stafford, Hayley Roth, Sarah Campbell, Samantha Brady, Valerie Fiers, FeiFan Yu, Andrew Tsourkas, Riley Payne, Meghan Pitts, Kyle Guldner, Tim Phillips, Breanna Tyrell, Colleen Ulke, Allison Snyder, Marianne Assogba, Holden Ohl, Ileine Sanchez, Benjamin Doranz, Joseph Rucker, Ross Chambers. CCR8 antibody drug conjugates: Targeting regulatory T cells for tumor sensitization [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 718.

Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8

Unveiling the structural mechanisms of nonpeptide ligand recognition and activation in human chemokine receptor CCR8

Cryo-EM structure and biochemical analysis of human chemokine receptor CCR8

Cryo-EM Structure and Biochemical Analysis of the Human Chemokine Receptor CCR8

Computational Studies of the Binding Modes of Ccr1 Antagonists

Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5

Abstract LB130: Identification of fully human CCR8 antibodies that demonstrate excellent ADCC function, potent blocking activity, and robust anti-tumor immune responses

Identification of novel human CC chemokine receptor 8 (CCR8) antagonists via the synthesis of naphthalene amide and sulfonamide isosteres

Sensing antibody functions with a novel CCR8-responsive engineered cell

Structural insights into the activation and inhibition of CXC chemokine receptor 3

Molecular Mechanisms of Antagonist Selectivity Against CCR2 and CCR5

Computational Analysis of the Structural Mechanism of Inhibition of Chemokine Receptor CXCR4 by Small Molecule Antagonists

Abstract 718: CCR8 antibody drug conjugates: Targeting regulatory T cells for tumor sensitization

Structural basis of CXC chemokine receptor 2 activation and signalling

Molecular Insights into Ligand Recognition and Activation of Chemokine Receptors CCR2 and CCR3

Structural basis for CCR6 modulation by allosteric antagonists

Fragment-based drug discovery of small molecule ligands for the human chemokine CCL28

Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody

Discovery and Mapping of an Intracellular Antagonist Binding Site at the Chemokine Receptor CCR2

Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer

Crystal Structure and Structural Mechanism of a Novel Anti-Human Immunodeficiency Virus Andd-Amino Acid-Containing Chemokine